...
首页> 外文期刊>Journal of neuro-oncology. >Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system
【24h】

Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system

机译:Toll样受体(TLR)和B细胞受体(BCR)信号分子在中枢神经系统原发性弥漫性大B细胞淋巴瘤中的差异表达

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Primary diffuse large B-cell lymphoma of the central nervous system (CNS DLBCL) is a distinct and aggressive lymphoma that is confined to CNS. Since, central nervous system is barrier-protected and immunologically silent; role of TLR/BCR signaling in pathogenesis and biology of CNS DLBCL is intriguing. Genomic mutations in key regulators of TLR/BCR signaling pathway (MYD88/CD79B/CARD11) have recently been reported in this disease. These observations raised possible implications in novel targeted therapies; however, expression pattern of molecules related to TLR/BCR pathways in this lymphoma remains unknown. We have analyzed the expression of 19 genes encoding TLR/BCR pathways and targets in CNS DLBCLs (n = 20) by Nanostring nCounter (TM) analysis and compared it with expression patterns in purified reactive B-lymphocytes and systemic diffuse large B cell lymphoma (DLBCL) (n = 20). Relative expression of TLR4, TLR5, TLR9, CD79B and BLNK was higher in CNS DLBCLs than in control B-lymphocytes; where as TLR7, MALT1, BCL10, CD79A and LYN was lower in CNS DLBCLs (P<0.0001). When compared with systemic DLBCL samples, higher expression of TLR9, CD79B, CARD11, LYN and BLNK was noted in CNS DLBCL ([1.5 fold change; P<0.01). The B cell receptor molecules like BLNK and CD79B were also associated with higher expression of MYD88 dependent TLRs (TLR4/5/9). In conclusion, we have shown over expression of TLR/BCR related genes or their targets, where genomic mutations have commonly been identified in CNS DLBCL. We have also demonstrated that TLR over expression closely relate with up regulation of genes associated with BCR pathway like CD79B/BLNK and CARD11, which play an important role in NF-kB pathway activation. Our results provide an important insight into the possibility of TLR and/or B-cell receptor signaling molecules as possible therapeutic targets in CNS DLBCL.
机译:原发性中枢神经系统弥漫性大B细胞淋巴瘤(CNS DLBCL)是局限在CNS中的一种独特且侵袭性的淋巴瘤。因为,中枢神经系统是屏障保护的,并且在免疫学上沉默。 TLR / BCR信号传导在中枢神经系统DLBCL的发病机理和生物学中的作用令人感兴趣。最近已经报道了这种疾病中TLR / BCR信号通路的关键调控因子(MYD88 / CD79B / CARD11)的基因组突变。这些发现对新型靶向疗法可能产生了影响。然而,该淋巴瘤中与TLR / BCR通路相关的分子的表达模式仍然未知。我们已通过Nanostring nCounter(TM)分析分析了CNS DLBCLs(n = 20)中编码TLR / BCR途径和靶标的19个基因的表达,并将其与纯化的反应性B淋巴细胞和全身弥漫性大B细胞淋巴瘤的表达模式进行了比较( DLBCL)(n = 20)。在CNS DLBCLs中,TLR4,TLR5,TLR9,CD79B和BLNK的相对表达高于对照B淋巴细胞。其中CNS DLBCL中的TLR7,MALT1,BCL10,CD79A和LYN较低(P <0.0001)。与系统性DLBCL样品相比,CNS DLBCL中TLR9,CD79B,CARD11,LYN和BLNK的表达更高([1.5倍变化; P <0.01)。像BLNK和CD79B这样的B细胞受体分子也与MYD88依赖性TLR(TLR4 / 5/9)的更高表达有关。总之,我们已经显示了TLR / BCR相关基因或它们的靶标的过度表达,而在CNS DLBCL中通常已鉴定出基因组突变。我们还证明了TLR过表达与BCR通路相关基因的上调密切相关,例如CD79B / BLNK和CARD11,它们在NF-kB通路激活中起着重要作用。我们的结果为TLR和/或B细胞受体信号分子作为中枢神经系统DLBCL的可能治疗靶标的可能性提供了重要的见识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号